CooperCompanies Acquires obp Surgical for $100 Million, Expanding Surgical Device Portfolio

02 August 2024 | Friday | News

The acquisition, featuring obp Surgical’s innovative single-use devices, aligns with CooperSurgical’s strategic growth, adding to its existing suite of medical technologies.
Picture Courtesy | Public Domain

Picture Courtesy | Public Domain

CooperCompanies announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with an integrated multi-LED light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source, for approximately $100 million. The products being acquired generated approximately $14.5 million of trailing twelve-month revenue. The acquisition is expected to be neutral to Cooper’s non-GAAP earnings per share in fiscal 2024 and accretive thereafter.

“This acquisition is a great strategic fit that builds upon CooperSurgical’s strong portfolio of leading medical devices,” said Al White, President and Chief Executive Officer of CooperCompanies. “obp Surgical’s differentiated products will integrate seamlessly into our business and allow us to provide clinicians with a broader range of innovative surgical technologies.”

The acquisition of obp Surgical’s distinctive ONETRAC portfolio of surgical retractors and suction devices complements CooperSurgical’s existing surgical portfolio including INSORB®, Lone Star®, and the Doppler Blood Flow Monitor.

“Our acquisition of obp Surgical demonstrates our commitment to our customers, rooted in a dedication to upholding the highest standards,” said Holly Sheffield, CooperSurgical President. “We are excited for our growing surgical portfolio to reach new heights with the addition of ONETRAC to the CooperSurgical product family, all to help ensure that healthcare providers are well-equipped with differentiated medical devices.”

CooperCompanies will report these assets as part of its Office and Surgical category within the CooperSurgical business beginning in its fiscal fourth quarter 2024.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close